BACKGROUND: Thromboxanes are produced in excess and platelets are activated in active @entity30 . Preliminary reports have suggested that @entity18648 , a dual @entity2871 synthase inhibitor and receptor antagonist, may have therapeutic benefit in @entity1 with @entity29 . AIMS: To investigate the efficacy of @entity18648 in @entity1 with active @entity30 . @entity1 AND METHODS: This was an international, multicentre, randomized, double-blind, placebo-controlled trial of 5 mg/day oral @entity18648 for 12 weeks in 85 @entity1 with moderately active @entity30 . Sixty @entity1 were randomized to receive @entity18648 , and 25 to placebo. The @entity30 activity index (CDAI) was used to assess disease activity: remission was defined as a CDAI < 150. Changes in clinical condition, as assessed by the Harvey-Bradshaw index, global evaluation by the investigator and the @entity1 , and blood measures of @entity32 , were used as secondary outcomes. RESULTS: The @entity1 ' mean (s.d.) CDAI at recruitment was 277 (68) in the @entity18648 treated group and 265 (70) in the placebo group. At their final assessment, 20 out of 60 (35%) @entity1 who had been given @entity18648 in an intention-to-treat analysis and seven out of 25 (28%) @entity1 given placebo were in remission (no significant difference). No significant differences in Harvey- Bradshaw index or global evaluation were noted between @entity1 given @entity18648 and those given placebo. Adverse events were similar in both groups. CONCLUSION: A 5-mg dose of oral @entity18648 was not more effective than placebo in inducing remission in @entity1 with moderately active @entity30 . If @entity2871 synthesis and platelet function are to be targeted for the treatment of @entity30 , more potent agents require development and assessment.

Lack of efficacy of @entity18648 , a XXXX synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active @entity30 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity18648 :: ('MESH:C060219', 'Chemical') :: ['ridogrel'] @entity2871 :: ('CHEBI:26995', 'Chemical') :: ['thromboxane'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity2871 :: (CHEBI:26995,Chemical) :: ['thromboxane']
